Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: A real world observational postmarketing surveillance

Journal of Association of Physicians of India

Volumn 58, Issue 2, 2010, Pages 77-83

  Rana, Rajiv ^a   Singh, Amarinder ^a  

^a Merck Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; BLOOD PRESSURE; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; INDIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INDIA; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75949096924     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gupta R. Meta-analysis of prevalence of hypertension in India. Indian Heart J 1997; 49: 43-8
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. J Am Med Assoc 1996; 275: 1571-6
3. Reddy S. Regional Case Studies - India. Nestle Nutr Workshop Ser Pediatr Program. 2009;63:15-24
4. Das SK, Sanyal K, Basu A. Study of urban community survey in India: growing trend of high prevalence of hypertension in a developing country. Int J Med Sci 2005; 2: 70-78
5. Gupta R; Trends in hypertension epidemiology in India. J Hum Hypertens 2004 Feb; 18(2): 73-8.
6. Hathial M. Blood pressure control among Indians with hypertension: the I-Target survey. J Indian Med Assoc 2007 Jul; 105: 401-2
7. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report; J Am Med Assoc 2003; 289: 2560-72
8. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
9. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68: 1239-72
10. Sellin L, StegbauerJ, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23: 2083-92
11. Smith DH.; Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68: 1207-25
12. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26 Suppl A: A33-7
13. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26: 61-76
14. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13
15. Barrios V, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545-58
16. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24 hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419-30
17. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91
18. Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009; 26: 61-79
19. Nakayama S, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13
20. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage-2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007; 9: 36-44
21. Saito I, Kushiro T, Ishikawa M, Matsushita Y, Sagawa K, Hiramatsu K, Komiya M.; Early antihypertensive efficacy of olmesartan medoxomil. J Clin Hypertens (Greenwich). 2008; 10: 930-5
22. Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-40
23. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17:425-32
24. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16(Suppl 2): S24-8
25. Van Mieghem W. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens 2001; 19: S152-3
26. Williams PA. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001; 19(suppl 2): S300
27. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;8(suppl):37C-43C
28. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003; 21: 61-74 83